Skip to main content

Table 5 Changes in baseline to endpoint measures for oxidative stress and inflammatory biomarkers in two groups

From: Randomized double blind clinical trial evaluating the Ellagic acid effects on insulin resistance, oxidative stress and sex hormones levels in women with polycystic ovarian syndrome

Variables Mean ± SD
Placebo(n = 28)
Mean ± SD
Ellagic acid (n = 29)
P1
TAC (mg/dL) Baseline 1.04 ± 0.03 1.03 ± 0.02 0.41
End 1.03 ± 0.03 1.91 ± 0.07 0.032
P2 0.358 0.028  
Mean Changes -0.01 ± 0.00 0.88 ± 0.05 0.041
MDA (mg/dL) Baseline 1.47 ± 0.06 1.51 ± 0.09 0.466
End 1.45 ± 0.07 0.8 ± 0.03 0.039
P2 0.611 0.032  
Mean Changes -0.02 ± 0.01 -0.71 ± 0.06 0.044
TNF-α (pg/ml) Baseline 17.01 ± 3.78 16.89 ± 4.02 0.41
End 16.91 ± 4.04 13.5 ± 3.61 0.033
P2 0.292 0.03  
Mean Changes -0.1 ± 0.26 -3.39 ± 0.41 0.038
CRP(ng/ml) Baseline 9.37 ± 3.19 9.51 ± 3.37 0.359
End 9.23 ± 2.87 7.01 ± 2.2 0.045
P2 0.256 0.033  
Mean Changes -0.14 ± 0.32 -2.5 ± 1.17 0.048
  1. Data are expressed as means ± SD. TAC Total antioxidant capacity, MDA Malondialdehyde, TNF-α Tumor necrosis factor alpha, CRP C-reactive protein
  2. P1: Comparison of the mean of oxidative stress and inflammatory biomarkers between the two groups of Ellagic acid and placebo (Independent samples t-test)
  3. P2: Comparison of mean of oxidative stress and inflammatory biomarkers in each group at baseline and end of study (Paired samples t-test)